Does the media prefer MNOV or SPRY?

In the previous week, ARS Pharmaceuticals had 15 more articles in the media than MediciNova. MarketBeat recorded 24 mentions for ARS Pharmaceuticals and 9 mentions for MediciNova. MediciNova's average media sentiment score of 0.19 beat ARS Pharmaceuticals' score of 0.12 indicating that MediciNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 21 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RLMD or MNOV?

In the previous week, MediciNova had 7 more articles in the media than Relmada Therapeutics. MarketBeat recorded 9 mentions for MediciNova and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.90 beat MediciNova's score of 0.19 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediciNova 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MNOV or TTRX?

In the previous week, MediciNova had 8 more articles in the media than Turn Therapeutics. MarketBeat recorded 9 mentions for MediciNova and 1 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.27 beat MediciNova's score of 0.19 indicating that Turn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MNOV or FENC?

In the previous week, MediciNova had 7 more articles in the media than Adherex Technologies. MarketBeat recorded 9 mentions for MediciNova and 2 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.61 beat MediciNova's score of 0.19 indicating that Adherex Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adherex Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MNOV or ENTA?

In the previous week, MediciNova had 4 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 9 mentions for MediciNova and 5 mentions for Enanta Pharmaceuticals. MediciNova's average media sentiment score of 0.19 beat Enanta Pharmaceuticals' score of 0.15 indicating that MediciNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enanta Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MediciNova (MNOV) Competitors

$1.78 +0.01 (+0.28%)

As of 12:04 PM Eastern

Compare

MNOV vs. SPRY, RLMD, TTRX, FENC, and ENTA

Should you buy MediciNova stock or one of its competitors? MediciNova's main competitors and comparable companies include ARS Pharmaceuticals (SPRY), Relmada Therapeutics (RLMD), Turn Therapeutics (TTRX), Adherex Technologies (FENC), and Enanta Pharmaceuticals (ENTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MediciNova compare to ARS Pharmaceuticals?

MediciNova (NASDAQ:MNOV) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

ARS Pharmaceuticals has a net margin of -184.24% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

MediciNova currently has a consensus target price of $7.75, indicating a potential upside of 335.39%. ARS Pharmaceuticals has a consensus target price of $25.00, indicating a potential upside of 514.25%. Given ARS Pharmaceuticals' higher probable upside, analysts plainly believe ARS Pharmaceuticals is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, ARS Pharmaceuticals had 15 more articles in the media than MediciNova. MarketBeat recorded 24 mentions for ARS Pharmaceuticals and 9 mentions for MediciNova. MediciNova's average media sentiment score of 0.19 beat ARS Pharmaceuticals' score of 0.12 indicating that MediciNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	21 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MediciNova has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 14.0% of MediciNova shares are owned by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MediciNova has higher earnings, but lower revenue than ARS Pharmaceuticals. MediciNova is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	213.69	-$12M	-$0.21	N/A
ARS Pharmaceuticals	$84.28M	4.80	-$171.30M	-$2.18	N/A

Summary

MediciNova and ARS Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does MediciNova compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MediciNova has higher revenue and earnings than Relmada Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
MediciNova	$410K	213.69	-$12M	-$0.21	N/A

Relmada Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Relmada Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-47.52%	-43.97%
MediciNova	-1,168.70%	-26.51%	-24.39%

Relmada Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 233.33%. MediciNova has a consensus target price of $7.75, indicating a potential upside of 335.39%. Given MediciNova's higher possible upside, analysts plainly believe MediciNova is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
MediciNova	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, MediciNova had 7 more articles in the media than Relmada Therapeutics. MarketBeat recorded 9 mentions for MediciNova and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.90 beat MediciNova's score of 0.19 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediciNova	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MediciNova beats Relmada Therapeutics on 8 of the 15 factors compared between the two stocks.

How does MediciNova compare to Turn Therapeutics?

MediciNova (NASDAQ:MNOV) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

MediciNova currently has a consensus price target of $7.75, suggesting a potential upside of 335.39%. Turn Therapeutics has a consensus price target of $9.00, suggesting a potential downside of 32.48%. Given MediciNova's stronger consensus rating and higher probable upside, equities research analysts clearly believe MediciNova is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.50

Turn Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
Turn Therapeutics	N/A	-230.84%	-53.19%

In the previous week, MediciNova had 8 more articles in the media than Turn Therapeutics. MarketBeat recorded 9 mentions for MediciNova and 1 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.27 beat MediciNova's score of 0.19 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.9% of MediciNova shares are owned by institutional investors. 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Turn Therapeutics has lower revenue, but higher earnings than MediciNova. Turn Therapeutics is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	213.69	-$12M	-$0.21	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

Summary

MediciNova beats Turn Therapeutics on 11 of the 15 factors compared between the two stocks.

How does MediciNova compare to Adherex Technologies?

MediciNova (NASDAQ:MNOV) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

MediciNova has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

Adherex Technologies has higher revenue and earnings than MediciNova. Adherex Technologies is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	213.69	-$12M	-$0.21	N/A
Adherex Technologies	$44.64M	8.03	-$9.74M	-$0.13	N/A

Adherex Technologies has a net margin of -6.09% compared to MediciNova's net margin of -1,168.70%. Adherex Technologies' return on equity of -5.71% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
Adherex Technologies	-6.09%	-5.71%	-2.37%

In the previous week, MediciNova had 7 more articles in the media than Adherex Technologies. MarketBeat recorded 9 mentions for MediciNova and 2 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.61 beat MediciNova's score of 0.19 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adherex Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.9% of MediciNova shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 14.0% of MediciNova shares are held by insiders. Comparatively, 10.7% of Adherex Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MediciNova presently has a consensus target price of $7.75, suggesting a potential upside of 335.39%. Adherex Technologies has a consensus target price of $17.00, suggesting a potential upside of 66.67%. Given MediciNova's stronger consensus rating and higher probable upside, equities research analysts clearly believe MediciNova is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Adherex Technologies beats MediciNova on 9 of the 16 factors compared between the two stocks.

How does MediciNova compare to Enanta Pharmaceuticals?

MediciNova (NASDAQ:MNOV) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Enanta Pharmaceuticals has a net margin of -96.89% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%

In the previous week, MediciNova had 4 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 9 mentions for MediciNova and 5 mentions for Enanta Pharmaceuticals. MediciNova's average media sentiment score of 0.19 beat Enanta Pharmaceuticals' score of 0.15 indicating that MediciNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enanta Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MediciNova currently has a consensus target price of $7.75, indicating a potential upside of 335.39%. Enanta Pharmaceuticals has a consensus target price of $19.00, indicating a potential upside of 46.60%. Given MediciNova's stronger consensus rating and higher probable upside, research analysts clearly believe MediciNova is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

MediciNova has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

MediciNova has higher earnings, but lower revenue than Enanta Pharmaceuticals. MediciNova is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	213.69	-$12M	-$0.21	N/A
Enanta Pharmaceuticals	$65.32M	5.78	-$81.89M	-$2.41	N/A

9.9% of MediciNova shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 14.0% of MediciNova shares are held by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

MediciNova beats Enanta Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get MediciNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNOV vs. The Competition

Export

Metric	MediciNova	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$87.86M	$12.15B	$7.14B	$13.35B
Dividend Yield	N/A	2.65%	2.53%	17.32%
P/E Ratio	-8.50	802.28	274.82	26.18
Price / Sales	214.29	756.64	613.38	92.44
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	2.10	10.63	11.30	6.38
Net Income	-$12M	$2.84B	$3.50B	$381.35M
7 Day Performance	-15.00%	-1.99%	-1.88%	-0.57%
1 Month Performance	9.51%	-6.29%	-6.20%	-4.46%
1 Year Performance	39.45%	-4.48%	7.50%	1.77%

MediciNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNOV MediciNova	2.718 of 5 stars	$1.79 +0.3%	$7.75 +334.2%	+39.1%	$87.86M	$410K	N/A	6	Gap Up
SPRY ARS Pharmaceuticals	2.0011 of 5 stars	$4.40 +6.5%	$25.00 +468.2%	-60.5%	$410.72M	$84.28M	N/A	200
RLMD Relmada Therapeutics	2.582 of 5 stars	$3.73 -1.6%	$12.00 +221.7%	+55.2%	$404.28M	N/A	N/A	17	Positive News
TTRX Turn Therapeutics	1.8055 of 5 stars	$13.41 +2.8%	$9.00 -32.9%	N/A	$388.44M	N/A	N/A	2
FENC Adherex Technologies	3.9768 of 5 stars	$10.80 -1.4%	$17.00 +57.4%	+3.2%	$383.89M	$59.22M	N/A	35

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNOV) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediciNova (MNOV) Competitors

MNOV vs. SPRY, RLMD, TTRX, FENC, and ENTA

How does MediciNova compare to ARS Pharmaceuticals?

Summary

How does MediciNova compare to Relmada Therapeutics?

Summary

How does MediciNova compare to Turn Therapeutics?

Summary

How does MediciNova compare to Adherex Technologies?

Summary

How does MediciNova compare to Enanta Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediciNova (MNOV) Competitors

MNOV vs. SPRY, RLMD, TTRX, FENC, and ENTA

How does MediciNova compare to ARS Pharmaceuticals?

Is MNOV or SPRY more profitable?

Do analysts recommend MNOV or SPRY?

Does the media prefer MNOV or SPRY?

Which has more volatility & risk, MNOV or SPRY?

Do institutionals & insiders have more ownership in MNOV or SPRY?

Which has better valuation & earnings, MNOV or SPRY?

Summary

How does MediciNova compare to Relmada Therapeutics?

Do institutionals & insiders have more ownership in RLMD or MNOV?

Which has higher valuation and earnings, RLMD or MNOV?

Which has more volatility & risk, RLMD or MNOV?

Is RLMD or MNOV more profitable?

Do analysts recommend RLMD or MNOV?

Does the media refer more to RLMD or MNOV?

Summary

How does MediciNova compare to Turn Therapeutics?

Do analysts recommend MNOV or TTRX?

Is MNOV or TTRX more profitable?

Does the media favor MNOV or TTRX?

Do institutionals & insiders hold more shares of MNOV or TTRX?

Which has stronger earnings & valuation, MNOV or TTRX?

Summary

How does MediciNova compare to Adherex Technologies?

Which has more risk & volatility, MNOV or FENC?

Which has better valuation and earnings, MNOV or FENC?

Is MNOV or FENC more profitable?

Does the media refer more to MNOV or FENC?

Do institutionals and insiders hold more shares of MNOV or FENC?

Do analysts rate MNOV or FENC?

Summary

How does MediciNova compare to Enanta Pharmaceuticals?

Is MNOV or ENTA more profitable?

Does the media refer more to MNOV or ENTA?

Do analysts rate MNOV or ENTA?

Which has more risk and volatility, MNOV or ENTA?

Which has higher earnings and valuation, MNOV or ENTA?

Do institutionals & insiders have more ownership in MNOV or ENTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools